0 CHECKOUT

Mesenchymal Stem Cells - Advances & Applications

  • ID: 3292443
  • August 2015
  • Region: Global
  • 171 Pages
  • BioInformant

FEATURED COMPANIES

  • Anterogen Co., Ltd.
  • CellTherapies P/L
  • Cesca Therapeutics Inc.
  • Kite Pharma Inc.
  • Medipost Co. Ltd.
  • NuVasive Inc.
  • MORE

The purpose of this global strategic report is to prepare executives of stem cell product companies, stem cell therapy companies, and stem cell industry investors, with the knowledge necessary to make informed, educated decisions about opportunities for commercialization within the rapidly-evolving mesenchymal stem cell (MSC) marketplace.
It is produced for:

- Management of Stem Cell Product Companies
- Management of Stem Cell Therapy Companies
- Stem Cell Industry Investors

It is designed to increase efficiency and effectiveness in:
1.Commercializing MSC research products, technologies, and cell-based therapies
2.Making intelligent MSC investment decisions
3.Launching high-demand MSC products
4.Capitalizing on new and emerging MSC industry trends
5.Dominating market share within the MSC marketplace
6.Understanding your strengths and weaknesses relative to the competition

Because mesenchymal stem cell researchers represent a rapidly growing, well-funded research community, this report presents strategies that research supply companies can use to develop product lines that will be of high value to the research community. It also presents READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Anterogen Co., Ltd.
  • CellTherapies P/L
  • Cesca Therapeutics Inc.
  • Kite Pharma Inc.
  • Medipost Co. Ltd.
  • NuVasive Inc.
  • MORE

1. REPORT OVERVIEW
1.1 Statement of the Report
1.2 EXECUTIVE SUMMARY

2. INTRODUCTION
2.1 Regenerative Medicine (RM) and Advanced Therapies Industry: A Brief Overview
2.10 Type of Financing for RM Industry
2.11 Major Regulatory Milestones in RM Industry
2.12 Major Data and Technology Events in RM Industry
2.13 Major Pharma and Biotech Companies Active in Advanced Therapies
2.14 Major Corporate Partnerships in RM Industry
2.15 Anticipated Major RM Clinical Events
2.16 Notable Deals and Acquisitions in RM, Cell and Gene Therapy Space, 2013-2014
2.17 Big Pharma’s Perception of RM
2.18.1 Major Therapeutic Opportunities for Big Pharma in Cell Therapy and RM
2.18.1.1 Current Opportunities
2.18.1.2 Near-Term Opportunities
2.18.1.3 Long-Term Opportunities
2.2 Global Breakdown of Major RM Industries by Region
2.3 Breakdown of Global RM Companies by Type
2.4 Number of Therapeutic Companies, Approved Products and Clinical Trials in RM Sector
2.5 Number of RM Clinical Trials by Phase of Development
2.6 Number of RM Companies by Disease Focus Area
2.7 Major Financial Events in RM Industry
2.8 Major Partnerships and Acquisitions in RM Industry
2.9 Total Financings in RM Industry by Segment

3. CELL THERAPY INDUSTRY: A BRIEF OVERVIEW
3.1 Types of Stem Cells Used in Cell Therapy
3.1.1 Human Embryonic Stem Cells (hESCs)
3.1.2 Induced Pluripotent Stem Cells (iPSCS)
3.1.3 Hematopoietic Stem Cells (HSCs)
3.1.4 Mesenchymal Stem Cells (MSCs)
3.1.5 Adipose Stem Cells (ASCs)
3.1.6 Neural Stem Cells (NSCs)
3.10 Combination of Cell and Gene Therapy Products in Development
3.11 Cancer Programs Utilizing the Combination of Cell and Immunotherapy
3.12 Major Commercially Available Cell Therapy Products
3.13 Cell Therapy Products Approved in South Korea
3.14 Cell Therapy Clinical Trials: An Overview
3.14.1 Cell Therapy Clinical Trials by Geography
3.14.2 Top Eight Countries in Cell Therapy Clinical Trials
3.14.3 Major Cell Types in Cell Therapy Clinical Trials
3.14.4 Major Disease Indications Addresses by Cell Therapy Clinical Trials
3.15 Fifteen Major Cell Therapies in Phase III
3.15.1 Prochymal
3.15.10 Renew
3.15.11 NT-501 (Renexus)
3.15.12 Neocart
3.15.13 DeNovo ET
3.15.14 MACI
3.15.2 Mesenchymal Precursor Cell (MPC)
3.15.3 MyoCell
3.15.4 Ixmyelocel-T
3.15.5 ELAD
3.15.6 HP802
3.15.7 StemEx (Carlecortemcel-L)
3.15.8 LaViv
3.15.9 GSK 2696273
3.16 Clinical Trial Failures in Cell Therapy in 2014
3.16.1 Failure of Phase II for MultiStem
3.16.10 Failed Efficacy Trial in AMI by Stempeucel
3.16.2 Failure of Cardio 133 Trial
3.16.3 Termination of AlloCure’s ACT-AKI Trial
3.16.4 Failed Stroke Trial in India
3.16.5 Failure of HeartiCellGram-AMI Trial
3.16.6 Failure of Adipose MSCs in ARDS
3.16.7 CD133+ in CLI Not Feasible
3.16.8 Failed MSC Trial for Multiple Sclerosis
3.16.9 Failure of Chinese Diabetes Trial
3.17 A Sampling of Stem and Progenitor Cell-Based Trials with 2014 Clinical Readouts
3.18 Major Cell Therapy Companies and their Locations
3.19 Involvement of Multinational Companies (MNCs) in Cell Therapy Sector
3.2 Cell Therapy Product Candidates in Late-Stage Clinical Development
3.3 Cell Therapy Product Candidates in Early-Stage Clinical Development
3.4 Cell Therapy Products Being Developed for Cardiovascular Indication
3.5 Cell Therapy Products Being Developed for Central Nervous System Indication
3.6 Cell Therapy Products Developed and Being Developed for Wound Care
3.7 Cell Therapy Products Developed and Being Developed for Spine and Orthopedics
3.8 Cell Therapy Products Being Developed for Diabetes
3.9 Cell Therapy Products Being Developed for Autoimmune Diseases

4. MESENCHYMAL STEM CELLS (MSCs): AN OVERVIEW
4.1 Biological Properties of MSCs Contributing to their Therapeutic Effects
4.1.1 MSCs’ Capacity to Migrate and Engraft
4.1.2 MSCs’ Differentiation Potential
4.1.3 MSCs’ Potential to Secrete Multiple Bioactive Molecules
4.1.4 MSCs’ Potential for Immunomodulatory Functions
4.1.5 Variable Immunophenotype of MSCs
4.2 Factors Impacting MSCs Acquisition
4.3 Major Clinical Sources of MSCs
4.3.1 Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
4.3.1.1 BMMSCs and Kidney
4.3.1.2 BMMSCs and Pancreas
4.3.1.3 BMMSCs and Heart
4.3.1.4 BMMSCs and Liver
4.3.1.5 BMMSCs and Brain
4.3.1.6 BMMSCs and Intestine
4.3.1.7 BMMSCs and Bone
4.3.2 Adipose-Derived Mesenchymal Stem Cells
4.3.2.1 Selected ADSC Secretomes and their Functions
4.3.3 Mesenchymal Stem Cells (MSCs) Derived from Wharton’s Jelly
4.3.3.1 Clinical Application Properties of WJ-MSCs
4.3.3.2 Immunoprivileged Status of WJ-MSCs
4.3.3.3 Clinical Applications of WJ-MSCs
4.3.4 Umbilical Cord Blood-Derived MSCs (UCBMSCs)
4.4 Dominance of MSCs in Cell Therapy Clinical Trials
4.5 Major Diseases Addressed by MSCs in Current Clinical Trials
4.5.1 MSCs for Treating Liver Diseases
4.5.10 MSCs in Wound Healing
4.5.11 Increasing Focus on Immunological Properties of MSCs
4.5.12 Percentage of MSCs Clinical Trials by Different Phases
4.5.13 Selected MSCs Late-Stage Pipeline Cell Therapies
4.5.2 MSCs for Neurodegenerative Diseases
4.5.3 Clinical Trials Using MSCs for Autoimmune Diseases
4.5.4 Clinical Trials Using MSCs for Diabetes
4.5.5 MSCs for Cardiovascular Repair
4.5.5.2 Application of MSCs in Joint Diseases
4.5.6 MSCs for Musculoskeletal Diseases
4.5.6.1 Studies Using MSCs for Musculoskeletal Indications by Leading Countries
4.5.7 MSCs in Neuron/Spinal Cord Diseases
4.5.8 MSC Infusion for GvHD
4.5.9 MSCs for Crohn’s Disease

5. A BRIEF OVERVIEW OF THE MARKET FOR STEM CELLS
5.1 Global Market for Stem Cells by Disease Indication

6. SELECTED COMPANY PROFILES
6.1 American Type Culture Collection Inc. (ATCC)
6.10 CellTherapies P/L
6.10.1 Services
6.10.2 Product
6.11 Cesca Therapeutics Inc.
6.11.1 Surgwerks
6.11.2 Cellwerks
6.11.3 AutoXress (AXP)
6.11.4 MarrowXpress (MXP)
6.11.5 Res-Q BMC
6.12 Cyagen Biosciences Inc.
6.12.1 Mesenchymal Stem Cells from Cyagen
6.12.10 General Cell Culture Supplements and Specialty Reagents from Cyagen
6.12.2 Adipose-Derived Mesenchymal Stem Cells from Cyagen
6.12.3 Mesenchymal Stem Cells with GFP from Cyagen
6.12.4 Adipose-Derived Mesenchymal Cells with GFP from Cyagen
6.12.5 Stem Cell Culture Media from Cyagen
6.12.6 Stem Cell Differentiation Media from Cynagen
6.12.7 Primary Cells from Cynagen
6.12.8 Cyagen’s Cryopreservation Media
6.12.9 Cyagen’s Primary Cell Culture Media
6.13 Cynata Therapeutics Ltd.
6.13.1 Cymerus Platform Technology
6.14 Cytori Therapeutics Inc.
6.14.1 Clinical Trial for Scleroderma
6.14.2 Clinical Trials for Osteoarthritis
6.15 Escape Therapeutics
6.16 Genlantis
6.17 Kite Pharma Inc.
6.17.1 Engineered Autologous Cell Therapy (eACT)
6.17.2 DC-Ad GM-CAIX
6.18 Life Technologies Corporation
6.19 Lonza Group Ltd.
6.19.1 Selected Products
6.2 Anterogen Co., Ltd.
6.2.1 Cupistem Injection
6.2.2 Queencell
6.20 Medipost Co. Ltd.
6.20.1 Cartistem
6.20.2 Neurostem
6.20.3 Pneumostem
6.21 Mesoblast Ltd.
6.21.1 Mesoblast’s Product Pipeline Overview
6.22 NuVasive Inc.
6.22.1 Osteocel
6.23 Octa Therapeutics Inc.
6.24 Organogenesis Inc.
6.24.1 Apligraf
6.24.2 Dermagraft
6.25 Orthofix International N.V.
6.25.1 Trinity Elite
6.25.2 Trinity Evolution
6.26 Osiris Therapeutics Inc.
6.26.1 Grafix
6.26.2 OvationOS
6.26.3 Cartiform
6.27 Pluristem Therapeutics Inc.
6.27.1 PLX Cells
6.28 PromoCell
6.29 Regeneus Ltd.
6.29.1 Products
6.3 Apceth GmbH & Co. KG
6.3.1 Apceth’s Research Areas
6.30 ScienCell Research Laboratories
6.31 Stemcell Technologies Inc.
6.32 Stemedica Cell Technologies Inc.
6.32.1 Stemedyne MSC
6.32.2 Stemedyne NSC
6.32.3 Stemedyne RPE
6.33 Stempeutics Research Pvt. Ltd.
6.33.1 Stempeucel
6.33.2 Stempeutron
6.33.3 Stempeucare
6.34 TiGenix N.V.
6.34.1 Cx601
6.34.2 Cx611
6.34.3 Cx621
6.35 Vericel Corporation
6.4 BioCardia Inc.
6.5 BioRestorative Therapies Inc.
6.5.1 brtxDISC
6.5.2 ThermoStem
6.6 Bone Therapeutics SA
6.6.1 PREOB
6.6.2 ALLOB
6.7 BrainStorm Cell Therapeutics Inc.
6.7.1 NurOwn
6.8 CellGenix Technologie Transfer GmbH
6.9 Celprogen Inc.

INDEX OF FIGURES

Figure 3.1: Number of Cell Therapy Clinical Trials, 2011-2014
Figure 3.2: Cell Therapy Clinical Trials (%) by Geography in 2014
Figure 3.3: Top Eight Countries in Cell Therapy Clinical Trials (%) in 2014
Figure 3.4: Major Cell Types in Cell Therapy Clinical Trials (Numbers) in 2014
Figure 3.5: Major Cell Therapy Clinical Trials (Numbers) by Indication in 2014
Figure 4.1: Schematic of Factors Impacting MSC Acquisition
Figure 4.2: Number of Clinical Trials Using MSCs, 2004-2014
Figure 4.3: Increasing Focus on the Immunological Properties of MSCs
Figure 4.4: Percentage of MSCs Clinical Trials by Different Phases
Figure 5.1: Global Market for Stem Cells, Stem Cell Services, Cord Blood Banking, Stem Cell Therapies and Bone Marrow Transplants, Through 2021
Figure 5.2: Global Market for Stem Cells by Disease Indication, Through 2021

INDEX OF TABLES

Table 2.10: Major Regulatory Milestones in RM Industry in 2014
Table 2.11: Major Data and Technology Events in RM Industry in 2014
Table 2.12: Major Pharma and Biotech Companies Active in Advanced Therapies in 2014
Table 2.13: Major Corporate Partnerships in RM Industry in 2014
Table 2.14: Anticipated Major RM Clinical Events in 2015
Table 2.15: NoTable Deals and Acquisitions in RM, Cell and Gene Therapy
Table 2.16: Big Pharma's Interest on Investing in RM by Sector
Table 2.17: Most Promising Areas in RM for Big Pharma
Table 2.1: Global Breakdown of Major RM Industries by Region

Table 2.2: Global Breakdown of RM Companies by Type, 2014
Table 2.3: Number of Therapeutic Companies, Approved Products and Clinical Trials, 2014
Table 2.4: Number of RM Clinical Trials by Phase in 2014
Table 2.5: Number of RM Companies by Disease Focus Area
Table:2.6: Major Financial Events in RM Industry in 2014
Table 2.7: Major Partnerships and Acquisitions in RM Industry in 2014
Table 2.8: Total Financings in RM Industry by Segment in 2014
Table 2.9: Type of Financing for RM Industry in 2013 and 2014
Table 3.10: Combination of Cell and Gene Therapy Products in Development
Table 3.11: Cancer Programs Utilizing the Combination of Cell and Immunotherapy
Table 3.12: Major Commercially Available Cell Therapy Products
Table 3.13: Cell Therapy Products Approved in South Korea
Table 3.14: A Sampling of Stem and Progenitor Cell-Based Trials with 2014 Readouts
Table 3.15: Major Cell Therapy Companies in the World
Table 3.16: Major Companies and Products in Development in Cell Therapy Sector
Table 3.1: Different Types of Stem Cells Used in Cell Therapy and their Characteristics
Table 3.2: Cell Therapy Product Candidates in Late-Stage Clinical Development
Table 3.3: Cell Therapy Product Candidates in Early-Stage Clinical Development
Table 3.4: Cell Therapy Products Being Developed for Cardiovascular Indication
Table 3.5: Cell Therapy Products Being Developed for Central Nervous System
Table 3.6: Cell Therapy Products Developed and Being Developed for Wound Care
Table 3.7: Cell Therapy Products for Spine and Orthopedics
Table 3.8: Cell Therapy Products Being Developed for Diabetes
Table 3.9: Cell Therapy Products Being Developed for Autoimmune Diseases
Table 4.10: Clinical and Experimental Therapies Using MSCs for Neural Diseases
Table 4.11: A Sample of Clinical Trials Using MSCs for Intestinal Diseases
Table 4.12: A Sample of Clinical Trials Using BMMSCs for Musculoskeletal Diseases
Table 4.13: ADSCs Transplantation in Clinical Trials by Region in Phase III, 2014
Table 4.14: Selected ADSC Secretomes and their Functions
Table 4.15: A Summary of Clinical Trials Using WJ-MSCs
Table 4.16: Clinical Trials Using UCBMSCs and Targeted Diseases
Table 4.17: Dominance of MSCs in 2014 Stem Cells Clinical Trials
Table 4.18: Clinical Trials Using MSCs by Disease Type, 2014
Table 4.19: A Sample of Clinical Trials Using MSCs for Liver Diseases
Table 4.1: Origin and Cell Typed Derived from MSCs
Table 4.20: A Sample of Clinical Trials Using MSCs for Neurodegenerative Diseases
Table 4.21: A Sample of Phase I and II Clinical Trials for Autoimmune Diseases
Table 4.22: A Sample of Clinical Trials Using MSCs for Diabetes
Table 4.23: A Sample of Clinical Trials Using MSCs for Cardiovascular Diseases
Table 4.24: Clinical Trials Involving MSCs for Bone and Cartilage Repair
Table 4.25: Studies Using MSCs for Musculoskeletal Indications by Countries in 2014
Table 4.26: A Sample of Current Clinical Trials Using MSCs for Osteoarthritis
Table 4.27: A Sample of Clinical Trials Involving MSCs for Bone and Cartilage Repair
Table 4.28: Clinical Trials Using MSCs for Neuron and Spinal Cord Diseases
Table 4.29: Clinical Experience of MSCs in GvHD Treatment
Table 4.2: Important Bioactive Molecules Secreted by MSCs and Their Functions
Table 4.30: A Sample of Clinical Trials Using MSCs for Crohn's Disease
Table 4.31: Clinical Studies Using MSCs for Wound Healing
Table 4.32: Selected MSCs Late-Stage Pipeline Therapies
Table 4.3: Immunomodulatory Effects of MSCs on Immune Cells
Table 4.4: Cell Surface Antigen Expressions of MSCs Isolaed from Different Sources
Table 4.5: Major Clinical Sources of MSCs
Table 4.6: A Sample of Clinical Trials Using BMMSCs for Kidney Diseases
Table 4.7: A Sample of Clinical Trials Using BMMSCs for Diabetes
Table 4.8: A Sample of Clinical Trials Using BMMSCs for Heart Diseases
Table 4.9: A Sample of Clinical Trials Using BMMSCs for Liver Diseases
Table 5.1: Global Market for Stem Cells, Through 2021
Table 5.2: Global Market for Stem Cells by Disease Indication, Through 2021
Table 6.10: Cyagen's Cryopreservation Media
Table 6.11: Cyagen's Primary Cell Culture Media
Table 6.12: General Cell Culture Supplements and Specialty Reagents from Cyagen
Table 6.13: Escape Therapeutics' Pipeline Products
Table 6.14: Kite Pharma's Pipeline and Clinical Trials
Table 6.15: Mesoblast's Product Pipeline Overview
Table 6.16: Octa's Pipeline of Therapeutic Programs
Table 6.17: Regeneus' Product Pipeline
Table 6.18: Stempeucel in Clinical Trials by Indication
Table 6.19: Vericel Corporation's Product Portfolio
Table 6.1: BioCardia's Product Pipeline Overview
Table 6.20: Summary Table for the Companies and Their Product Types
Table 6.2: Bone Therapeutics' Product Pipeline
Table 6.3: Cyagen's Mesenchymal Cells
Table 6.4: Cyagen's Adipose-Derived MSCs
Table 6.5: Cyagen's MSCs with GFP
Table 6.6: Cyagen's Adipose-Derived MSCs with GFP
Table 6.7: Cyagen's Stem Cell Culture Media
Table 6.8: Cyagen's Stem Cell Differentiation Media
Table 6.9: Primary Cells from Cyagen

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Anterogen Co., Ltd.
  • CellTherapies P/L
  • Cesca Therapeutics Inc.
  • Kite Pharma Inc.
  • Medipost Co. Ltd.
  • NuVasive Inc.
  • MORE

The purpose of this global strategic report is to prepare executives of stem cell product companies, stem cell therapy companies, and stem cell industry investors, with the knowledge necessary to make informed, educated decisions about opportunities for commercialization within the rapidly-evolving mesenchymal stem cell (MSC) marketplace.
It is produced for:

- Management of Stem Cell Product Companies
- Management of Stem Cell Therapy Companies
- Stem Cell Industry Investors

It is designed to increase efficiency and effectiveness in:
1.Commercializing MSC research products, technologies, and cell-based therapies
2.Making intelligent MSC investment decisions
3.Launching high-demand MSC products
4.Capitalizing on new and emerging MSC industry trends
5.Dominating market share within the MSC marketplace
6.Understanding your strengths and weaknesses relative to the competition

Because mesenchymal stem cell researchers represent a rapidly growing, well-funded research community, this report presents strategies that research supply companies can use to develop product lines that will be of high value to the research community. It also presents valuable content for cellular therapy companies, both quantifying and qualifying the market for MSC based therapeutics and related clinical applications. Thirdly, it is important for pharmaceutical companies to understand underlying market forces and to assess areas of MSC research progress as opportunities for drug and therapy development, including how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.

As such, this global strategic report explores topics of interest to three types of industry participants: Research supply companies, cell therapy companies, and drug development companies.

Because it is vital to assess trends that are occurring within the MSC market, the report also considers a range of important trend data for the MSC market, including trend rate data for MSC clinical trials, patents, grants, scientific publications, and more. Additionally, it considers the driving force for mergers and acquisitions that are occurring within the MSC market. With 4 zettabytes (10^21st bytes) of data now in existence worldwide, this report eliminates superficial information and drill down to the key metrics that will provide executives and investors with the data required to make educated decisions that will drive revenue.

In addition, executives and investors must to have a clear understanding of opportunities and threats occurring within the MSC marketplace. As the technology surrounding MSC derivation and differentiation advances, new opportunities for scaling up the manufacture and distribution of MSC research products and cell-based therapies has emerged. As clinical trials investigating MSCs increase in number, more cell therapy companies are also exploring clinical applications of MSCs and becoming competitive threats within the marketplace. Other examples of emerging threats within the MSC industry include the potential for inconsistent or negative clinical findings, competing technologies, and fluctuating government stances on whether manipulation of stem cells prior to transplantation into humans should be allowed (a current “hot topic” among regulatory bodies within the U.S. and other regions). In the rapidly-evolving MSC marketplace, being fully informed about both opportunities and threats is an essential aspect of being able to survive and thrive.

For a decade or so, MSCs were largely perceived to be a supportive, feeder layer for hematopoietic stem cells (HSCs). Then, sentiment within the research community swung strongly in the opposite direction, with MSCs hastily labeled as “stem cells,” despite demonstrating a considerably limited differentiation potential. This characterization was misleading and drove research towards outcomes that involved semi-differentiated and often non-engrafting cells. Because MSC differentiation often does not explain the benefits of MSC treatment, the answer to how MSCs exert their effects is still being explored across the public, private, academic, and government sectors.

Indeed, the traditional view that mesenchymal stem cells heal by maturing into replacement cells for damaged tissue is either partially (or fully) untrue. Current research now suggests that the power of MSCs more likely comes from their ability to regulate the immune response and influence the human body’s own regenerative machinery. This understanding is critical to pursing effective avenues for the commercialization of MSC products, technologies, and therapies.

The content and statistics contained in this report were compiled using a broad range of sources, including:

- Stem Cell Grant Funding Database (RePORT Database, CIRM, MRC, Wellcome Trust - UK)
- Stem Cell Patent Database (United States Patent and Trade Office, World Intellectual Property Organization)
- Stem Cell Clinical Trial Database (ClinicalTrials.gov, International Clinical Trials Registry Platform, European Union Clinical Trials Register )
- Stem Cell Scientific Publication Database (PubMed, Highwire Press, Google Scholar)
- Stem Cell Product Launch Announcements (Trade Journals, Google News)
- Stem Cell Industry Events (Google News, Google Alerts)
- Stem Cell Company News (SEC Filings, Investor Publications, Historic Performance)
- International Surveys (Electronically Distributed End-User Surveys)

Key findings within this report include:

- Trend Rate Data for MSC Grants, Clinical Trials, and Scientific Publications
- Analysis of MSC Patent Environment, including Key Patents and Patent Trends
- Advances in MSC Research Applications
- Crucial Advances in MSC Therapy Development
- Research Priorities by Market Segment
- Geographical Assessment of MSC Innovation
- Competitive Environment Analysis
- Market Size Determinations
- Company Profiles for MSC Industry Leaders
- And Much More

In summary, the mesenchymal stem cell marketplace is composed of several sectors experiencing strong growth. Claim this global strategic report to become informed, to gain a strategic advantage over your competition, and most importantly, to take advantage of important MSC industry trends.

Note: Product cover images may vary from those shown

- Anterogen Co., Ltd.
- BioCardia Inc.
- BioRestorative Therapies Inc.
- BrainStorm Cell Therapeutics Inc.
- CellTherapies P/L
- Celprogen Inc.
- Cesca Therapeutics Inc.
- Cyagen Biosciences Inc.
- Kite Pharma Inc.
- Life Technologies Corporation
- Lonza Group Ltd.
- Medipost Co. Ltd.
- Mesoblast Ltd.
- NuVasive Inc.
- Orthofix International N.V.
- Osiris Therapeutics Inc.
- Pluristem Therapeutics Inc.
- Regeneus Ltd.
- ScienCell Research Laboratories
- Stemcell Technologies Inc.
- Stemedica Cell Technologies Inc.
- Vericel Corporation

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS

Our Clients

  • Amgen Inc.
  • Bayer AG
  • Bio-Rad Laboratories, Inc.
  • Beckman Coulter, Inc.
  • Novartis AG
  • Baxter International Inc.